Success Story: Driving Innovation in Immunology and Cell Therapy: NIW Approval for an Associate Research Scientist
Client’s Testimonial:
"Working with Chen Immigration Law Associates was an outstanding experience from start to finish. Their team was highly professional, knowledgeable, and responsive throughout the entire EB-2 NIW process. They carefully guided me in preparing a strong petition, provided clear instructions at every stage, and were always available to answer my questions.
I was especially impressed by their attention to detail and their ability to present my research in a compelling way. Thanks to their expertise, my I-140 petition was approved without a Request for Evidence!”
On July 8th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for an Associate Research Scientist in the Field of Immunology (Approval Notice).
General Field: Immunology
Position at the Time of Case Filing: Associate Research Scientist
Country of Origin: Italy
State of Residence at the Time of Filing: New York
Approval Notice Date: July 8th, 2026
Processing Time: 19 months, 2 days (Premium Processing Requested)
Case Summary:
The client's research focused on identifying the molecular mechanisms responsible for cellular immune processes to support the development of more effective therapies for cancer and type 1 diabetes. The petition was approved on July 8th, 2026, following a Premium Processing request submitted on May 5th, 2026.
Rather than concentrating on a single disease, the client's research examined several interconnected aspects of immune regulation, including cancer immune evasion, resistance to immunotherapy, liver metastasis, and T cell engineering. North America Immigration Law Group (Chen Immigration Law Associates) demonstrated that these projects contributed to one broader objective: improving how immune-based therapies are designed and applied. The petition also explained that this work supported advances in biotechnology, an area recognized by the U.S. government as a critical and emerging technology.
To demonstrate that the client was well positioned to continue this work, we highlighted a growing record of scientific achievement, including:
- Ph.D. in Genetics and Molecular Biology
- 4 peer-reviewed journal articles, 1 first-authored conference abstract, and 1 granted patent
- 70 citations
- 9 completed peer reviews
- Funding from the National Cancer Institute, the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Juvenile Diabetes Research Foundation
These accomplishments showed that the client's work had already earned recognition within the international research community.
The petition further demonstrated that other scientists had relied upon the client's discoveries to advance studies involving cancer biology, liver metastasis, immune regulation, aging, and cardiovascular disease. This pattern of independent reliance illustrated that the research had become a useful foundation for subsequent investigations rather than remaining isolated findings. Four recommendation letters reinforced these contributions.
By organizing the evidence around the client's long-term research direction instead of individual projects, we demonstrated both the national importance of the proposed endeavor and the client's ability to continue advancing it. We are delighted that this NIW petition received a favorable decision and wish the client continued success in developing immunology research that improves cancer treatment and autoimmune disease therapies.